vs
MESA LABORATORIES INC（MLAB）与Star Equity Holdings, Inc.（STRR）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是Star Equity Holdings, Inc.的1.1倍（$65.1M vs $56.8M），MESA LABORATORIES INC净利率更高（5.6% vs -3.0%，领先8.6%），Star Equity Holdings, Inc.同比增速更快（69.0% vs 3.6%），MESA LABORATORIES INC自由现金流更多（$18.0M vs $-9.0M），过去两年Star Equity Holdings, Inc.的营收复合增速更高（29.5% vs 5.1%）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
该公司信息存在混淆，Stars Equity Holdings, Inc.为一家投资控股企业，而描述提及的Artists Equity是由本·阿弗莱克和马特·达蒙两位演员兼制片人于2022年11月创立的美国制片公司。
MLAB vs STRR — 直观对比
营收规模更大
MLAB
是对方的1.1倍
$56.8M
营收增速更快
STRR
高出65.4%
3.6%
净利率更高
MLAB
高出8.6%
-3.0%
自由现金流更多
MLAB
多$27.0M
$-9.0M
两年增速更快
STRR
近两年复合增速
5.1%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $56.8M |
| 净利润 | $3.6M | $-1.7M |
| 毛利率 | 64.2% | — |
| 营业利润率 | 12.2% | -0.2% |
| 净利率 | 5.6% | -3.0% |
| 营收同比 | 3.6% | 69.0% |
| 净利润同比 | 316.6% | -192.1% |
| 每股收益（稀释后） | $0.65 | $-0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLABSTRR
| Q4 25 | $65.1M | $56.8M | ||
| Q3 25 | $60.7M | $48.0M | ||
| Q2 25 | $59.5M | $35.5M | ||
| Q1 25 | $62.1M | $31.9M | ||
| Q4 24 | $62.8M | $33.6M | ||
| Q3 24 | $57.8M | $36.9M | ||
| Q2 24 | $58.2M | $35.7M | ||
| Q1 24 | $58.9M | $33.9M |
净利润MLABSTRR
| Q4 25 | $3.6M | $-1.7M | ||
| Q3 25 | $2.5M | $-1.8M | ||
| Q2 25 | $4.7M | $-688.0K | ||
| Q1 25 | $-7.1M | $-1.8M | ||
| Q4 24 | $-1.7M | $-585.0K | ||
| Q3 24 | $3.4M | $-846.0K | ||
| Q2 24 | $3.4M | $-441.0K | ||
| Q1 24 | $-254.6M | $-2.9M |
毛利率MLABSTRR
| Q4 25 | 64.2% | — | ||
| Q3 25 | 61.5% | 43.0% | ||
| Q2 25 | 62.0% | — | ||
| Q1 25 | 61.8% | — | ||
| Q4 24 | 63.3% | — | ||
| Q3 24 | 61.3% | 50.5% | ||
| Q2 24 | 64.0% | — | ||
| Q1 24 | 62.1% | — |
营业利润率MLABSTRR
| Q4 25 | 12.2% | -0.2% | ||
| Q3 25 | 7.8% | -3.4% | ||
| Q2 25 | 5.1% | -0.6% | ||
| Q1 25 | 2.4% | -5.4% | ||
| Q4 24 | 9.2% | -0.4% | ||
| Q3 24 | 6.1% | -1.2% | ||
| Q2 24 | 9.6% | -0.5% | ||
| Q1 24 | -460.6% | -9.0% |
净利率MLABSTRR
| Q4 25 | 5.6% | -3.0% | ||
| Q3 25 | 4.1% | -3.7% | ||
| Q2 25 | 8.0% | -1.9% | ||
| Q1 25 | -11.4% | -5.5% | ||
| Q4 24 | -2.7% | -1.7% | ||
| Q3 24 | 5.9% | -2.3% | ||
| Q2 24 | 5.8% | -1.2% | ||
| Q1 24 | -432.2% | -8.6% |
每股收益（稀释后）MLABSTRR
| Q4 25 | $0.65 | $-0.49 | ||
| Q3 25 | $0.45 | $-0.54 | ||
| Q2 25 | $0.85 | $-0.23 | ||
| Q1 25 | $-1.30 | $-0.59 | ||
| Q4 24 | $-0.31 | $-0.21 | ||
| Q3 24 | $0.63 | $-0.28 | ||
| Q2 24 | $0.62 | $-0.15 | ||
| Q1 24 | $-47.26 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.0M | $10.3M |
| 总债务越低越好 | $68.4M | — |
| 股东权益账面价值 | $186.7M | $65.7M |
| 总资产 | $434.8M | $113.2M |
| 负债/权益比越低杠杆越低 | 0.37× | — |
8季度趋势，按日历期对齐
现金及短期投资MLABSTRR
| Q4 25 | $29.0M | $10.3M | ||
| Q3 25 | $20.4M | $15.4M | ||
| Q2 25 | $21.3M | $16.8M | ||
| Q1 25 | $27.3M | $16.6M | ||
| Q4 24 | $27.3M | $17.0M | ||
| Q3 24 | $24.3M | $15.8M | ||
| Q2 24 | $28.5M | $14.7M | ||
| Q1 24 | $28.2M | $20.4M |
总债务MLABSTRR
| Q4 25 | $68.4M | — | ||
| Q3 25 | $69.4M | $6.5M | ||
| Q2 25 | $70.3M | — | ||
| Q1 25 | $71.3M | — | ||
| Q4 24 | $72.2M | $0 | ||
| Q3 24 | $73.1M | — | ||
| Q2 24 | $74.1M | — | ||
| Q1 24 | — | — |
股东权益MLABSTRR
| Q4 25 | $186.7M | $65.7M | ||
| Q3 25 | $178.5M | $67.8M | ||
| Q2 25 | $172.5M | $40.1M | ||
| Q1 25 | $159.8M | $39.5M | ||
| Q4 24 | $155.2M | $40.4M | ||
| Q3 24 | $161.5M | $42.9M | ||
| Q2 24 | $150.7M | $42.6M | ||
| Q1 24 | $145.4M | $44.3M |
总资产MLABSTRR
| Q4 25 | $434.8M | $113.2M | ||
| Q3 25 | $430.4M | $117.1M | ||
| Q2 25 | $435.7M | $55.6M | ||
| Q1 25 | $433.3M | $53.2M | ||
| Q4 24 | $433.3M | $52.6M | ||
| Q3 24 | $454.1M | $52.6M | ||
| Q2 24 | $440.4M | $52.6M | ||
| Q1 24 | $446.8M | $52.6M |
负债/权益比MLABSTRR
| Q4 25 | 0.37× | — | ||
| Q3 25 | 0.39× | 0.10× | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.47× | 0.00× | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.49× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.8M | $-7.3M |
| 自由现金流经营现金流 - 资本支出 | $18.0M | $-9.0M |
| 自由现金流率自由现金流/营收 | 27.7% | -15.8% |
| 资本支出强度资本支出/营收 | 1.1% | 3.0% |
| 现金转化率经营现金流/净利润 | 5.17× | — |
| 过去12个月自由现金流最近4个季度 | $37.9M | $-13.0M |
8季度趋势，按日历期对齐
经营现金流MLABSTRR
| Q4 25 | $18.8M | $-7.3M | ||
| Q3 25 | $8.2M | $-2.7M | ||
| Q2 25 | $1.9M | $139.0K | ||
| Q1 25 | $12.7M | $-802.0K | ||
| Q4 24 | $18.1M | $-2.8M | ||
| Q3 24 | $5.3M | $1.3M | ||
| Q2 24 | $10.7M | $-4.3M | ||
| Q1 24 | $12.9M | $-1.8M |
自由现金流MLABSTRR
| Q4 25 | $18.0M | $-9.0M | ||
| Q3 25 | $7.1M | $-3.4M | ||
| Q2 25 | $884.0K | $102.0K | ||
| Q1 25 | $11.9M | $-808.0K | ||
| Q4 24 | $17.3M | $-2.8M | ||
| Q3 24 | $3.5M | $1.3M | ||
| Q2 24 | $9.9M | $-4.3M | ||
| Q1 24 | $12.3M | $-1.8M |
自由现金流率MLABSTRR
| Q4 25 | 27.7% | -15.8% | ||
| Q3 25 | 11.7% | -7.0% | ||
| Q2 25 | 1.5% | 0.3% | ||
| Q1 25 | 19.2% | -2.5% | ||
| Q4 24 | 27.6% | -8.3% | ||
| Q3 24 | 6.0% | 3.4% | ||
| Q2 24 | 16.9% | -12.0% | ||
| Q1 24 | 21.0% | -5.3% |
资本支出强度MLABSTRR
| Q4 25 | 1.1% | 3.0% | ||
| Q3 25 | 1.8% | 1.3% | ||
| Q2 25 | 1.7% | 0.1% | ||
| Q1 25 | 1.2% | 0.0% | ||
| Q4 24 | 1.3% | 0.1% | ||
| Q3 24 | 3.1% | 0.0% | ||
| Q2 24 | 1.5% | 0.0% | ||
| Q1 24 | 0.9% | 0.0% |
现金转化率MLABSTRR
| Q4 25 | 5.17× | — | ||
| Q3 25 | 3.32× | — | ||
| Q2 25 | 0.40× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 3.17× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
STRR
| Revenue From Other Contracts With Customers | $27.6M | 49% |
| Other | $24.3M | 43% |
| Energy Services Segment | $4.9M | 9% |
